Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.

de Masson A, Bouaziz JD, Peffault de Latour R, Wittnebel S, Ribaud P, Rubio MT, Micol JB, Suarez F, Nguyen S, Dalle JH, Yakouben K, Robin M, Xhaard A, Adès L, Bourhis JH, Rybojad M, Bagot M, Socié G.

Blood. 2012 Dec 13;120(25):5089-90. doi: 10.1182/blood-2012-09-453928. No abstract available.

2.

Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.

Moreno-Romero JA, Fernández-Avilés F, Carreras E, Rovira M, Martínez C, Mascaró JM Jr.

Arch Dermatol. 2008 Sep;144(9):1106-9. doi: 10.1001/archderm.144.9.1106. No abstract available.

PMID:
18794453
3.

Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.

Kim H, Kim NH, Kang HJ, Lee JW, Kim MS, Park KD, Shin HY, Ahn HS.

Pediatr Transplant. 2012 Dec;16(8):910-2. doi: 10.1111/petr.12004. Epub 2012 Oct 11. No abstract available.

PMID:
23050745
4.

Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.

Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I.

Bone Marrow Transplant. 2008 Dec;42(11):757-60. doi: 10.1038/bmt.2008.252. Epub 2008 Sep 1.

PMID:
18762765
5.

Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.

Stadler M, Ahlborn R, Kamal H, Diedrich H, Buchholz S, Eder M, Ganser A.

Blood. 2009 Oct 22;114(17):3718-9; author reply 3719-20. doi: 10.1182/blood-2009-07-231159. No abstract available.

6.

A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.

Bibi Y, Gottlieb AB.

J Am Acad Dermatol. 2008 Oct;59(4):654-8. doi: 10.1016/j.jaad.2008.04.034. Epub 2008 Jun 20. Review.

PMID:
18571768
7.

A call for more dermatologic input into chronic graft-vs-host disease clinical trials.

Cowen EW.

Arch Dermatol. 2009 Mar;145(3):337-8. doi: 10.1001/archdermatol.2008.606. No abstract available.

PMID:
19289778
8.

Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate.

Inamo Y, Ochiai T.

Pediatr Dermatol. 2013 Nov-Dec;30(6):e191-3. doi: 10.1111/j.1525-1470.2012.01882.x. Epub 2012 Oct 2.

PMID:
23025697
9.

Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.

Zerr P, Distler A, Palumbo-Zerr K, Tomcik M, Vollath S, Dees C, Egberts F, Tinazzi I, Del Galdo F, Distler O, Schett G, Spriewald BM, Distler JH.

Am J Pathol. 2012 Nov;181(5):1672-80. doi: 10.1016/j.ajpath.2012.07.017. Epub 2012 Aug 31.

PMID:
22940072
10.

Imatinib treatment of generalized localized scleroderma (morphea).

Moinzadeh P, Krieg T, Hunzelmann N.

J Am Acad Dermatol. 2010 Nov;63(5):e102-4. doi: 10.1016/j.jaad.2010.02.030. No abstract available.

PMID:
20950732
11.

Is imatinib mesylate a promising drug in systemic sclerosis?

van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM.

Arthritis Rheum. 2008 Aug;58(8):2549-52. doi: 10.1002/art.23648.

12.

[Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].

Martínez C.

Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:69-71. Review. Spanish.

PMID:
21381292
13.

A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.

Lazar J, Poonawalla T, Teng JM.

Pediatr Dermatol. 2011 Mar-Apr;28(2):172-5. doi: 10.1111/j.1525-1470.2010.01301.x. Epub 2011 Mar 15.

PMID:
21504445
14.

Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?

Papadakis V, Karakasis D, Sfikakis PP, Baltadakis I, Apostolidis J, Evangelou K, Gorgoulis VG, Harhalakis N.

Leuk Lymphoma. 2009 Mar;50(3):471-4. doi: 10.1080/10428190802668881. No abstract available.

PMID:
19253137
15.

Imatinib mesylate treatment of nephrogenic systemic fibrosis.

Kay J, High WA.

Arthritis Rheum. 2008 Aug;58(8):2543-8. doi: 10.1002/art.23696.

16.

The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.

Soria A, Cario-André M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taïeb A.

Dermatology. 2008;216(2):109-17. doi: 10.1159/000111507. Epub 2008 Jan 23.

PMID:
18216472
17.

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.

Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, Jouet JP, Yakoub-Agha I.

Blood. 2009 Jul 16;114(3):719-22. doi: 10.1182/blood-2009-02-204750. Epub 2009 Mar 16.

18.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators..

N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.

19.

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.

Arthritis Rheum. 2007 Jan;56(1):311-22.

20.

Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?

Mendoza FA, Jiménez SA.

Arthritis Rheum. 2011 Nov;63(11):3199-203. doi: 10.1002/art.30545. No abstract available.

Supplemental Content

Support Center